However, pharmacological inhibition of RIPK1 in ApoESA/SA mice, a model for investigating advanced atherosclerosis, only reduces plaque lesion in early stage, and promotes more atherosclerosis lesions in late stage [148]. The gene discussed is RIPK1; the disease is atherosclerosis.